A new study, presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11–14 May) found that a once-weekly dose of tirzepatide can lead to significant and consistent weight loss ...

A sweeping review of dozens of clinical trials suggests that today’s most widely used GLP-1 receptor agonist drugs produce broadly consistent weight-loss results across age, race, ethnicity, and ...

A new once-daily pill may raise the bar for weight loss meds. Ozempic, Mounjaro and similar drugs that mimic the GLP-1 hormone the body naturally produces after eating can cause significant weight ...

A recent small study has found that people may be able to maintain their weight loss with fewer GLP-1 injections, but this strategy may not be effective for everyone.

Keep losing and gaining the same weight? These weekend habits could be the reason.

Learn why experts advise against stopping and restarting GLP-1 drugs, the health risks of weight yo-yoing, and how to manage long-term weight loss safely.

The couple ate home-cooked meals, walked 30-40 minutes a day, avoided refined carbohydrates, and prioritised protein ...

While GLP-1 drugs can be effective for weight loss, they are not necessarily a permanent solution. Therefore, the duration of treatment can vary.

Here’s something worth knowing if you’ve ever logged miles on a treadmill and wondered why the scale isn’t moving: you’re not doing it wrong. The relationship between exercise and weight loss is a ...

Supplies of high-demand obesity treatments are improving, but that doesn’t mean it's easier to get them. Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key ...

Eli Lilly warns some Medicare plans may exceed the $50 monthly cap for weight‑loss drugs under a new CMS model.

According to a new study, a once-weekly dose of tirzepatide can lead to significant, sustained weight loss for up to 3 years in adults with overweight or obesity who do not have diabetes. The findings ...